BIOALLIANCE PHARMA : Disclosure of total number of voting rights and number of shares in the capital at December 31, 2010

Regulatory News:

BioAlliance Pharma (Paris:BIO):

Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority):

Date		Total number of outstanding shares		Total number of voting rights
December 31, 2010		13, 536,072		Theoretical number of voting rights: 13, 536,072 (including treasury shares) Number of real voting rights: 13, 506,034 (without treasury shares)

About BioAlliance Pharma

Dedicated to cancer and supportive care – cancer related pathologies, chemotherapy and radiotherapy induced complications and opportunistic infections in immunocompromised patients – BioAlliance conceives and develops innovative products, especially in the hospital setting and for orphan or rare diseases.

BioAlliance Pharma SA
Dominique Costantini, President and CEO
Tel.: [phone]
[e-mail]
or
Nicolas Fellmann, CFO
Tel.: [phone]
[e-mail]
or
ALIZE RP
Caroline Carmagnol, [phone]
[e-mail]